1. Home
  2. Insights
  3. Blog
  4. The new era of COPD drug development: How precision medicine is reshaping clinical strategy

The new era of COPD drug development

How precision medicine is reshaping clinical strategy

After decades of incremental progress, COPD drug development is entering one of its most innovative periods. The approval of biologics and advances in biomarker-driven development are transforming how sponsors identify patients, generate evidence and differentiate assets in an increasingly competitive landscape.

COPD patho-epidemiology

Chronic obstructive pulmonary disease (COPD) is a heterogeneous, progressive lung disease characterised by persistent airflow limitation, chronic respiratory symptoms, and recurrent exacerbations. Pathologically, COPD develops from a combination of small airway disease (bronchiolitis) and parenchymal destruction (emphysema), typically driven by long-term exposure to noxious particles such as cigarette smoke. These processes result in airway narrowing, mucus hypersecretion, and impaired gas exchange. However, increasing understanding of disease biology has demonstrated that COPD is not a single disease entity, but a spectrum of distinct biological and clinical phenotypes.

Traditionally, COPD has been viewed as a neutrophil dominated inflammatory disorder. It is now recognised that the disease encompasses multiple immunological endotypes. Among the most clinically relevant is eosinophilic COPD, where inflammation is driven by type 2 (T2) pathways involving cytokines such as IL‑4, IL‑5, and IL‑13. This subgroup has emerged as a key focus for precision medicine approaches and biologic drug development.

From an epidemiological perspective, COPD continues to remain a major global health burden, affecting over 300 million people worldwide and accounting for approximately 3–3.5 million deaths annually, making it one of the leading causes of mortality globally. Importantly, up to 20–40% of patients exhibit elevated blood eosinophil levels, identifying a sizable population with distinct biology and therapeutic responsiveness. For drug developers, this growing understanding of COPD heterogeneity is reshaping development strategies, enabling more targeted approaches to patient selection, trial design and treatment evaluation.

Eosinophilic COPD: A treatable trait

Eosinophilic COPD is characterised by elevated blood eosinophil counts and may account for up to 20–40% of COPD patients, many of whom experience frequent and severe exacerbations despite optimal inhaled therapy. Increasing evidence suggests that eosinophilic inflammation represents a distinct disease endotype associated with enhanced responsiveness to corticosteroids and, more recently, targeted biologic therapies. This subgroup has emerged as one of the most clinically relevant treatable traits in COPD, providing an opportunity to move beyond a traditional one-size-fits-all treatment approach.1 The success of biomarker-guided biologic development in eosinophilic COPD has also helped establish a broader framework for more targeted approaches to respiratory disease management, with blood eosinophils serving as a clinically practical biomarker for patient identification and treatment selection.

From symptom control to targeted therapy

COPD has entered a new era of precision medicine, driven by new drug approvals and a rapidly evolving clinical development landscape. For several decades, COPD treatment relied on symptom control through inhaled bronchodilators and corticosteroids therapies that improved symptoms but did little to modify disease biology. Lately, however, the focus has shifted decisively toward targeting specific inflammatory pathways, with eosinophilic COPD emerging as the most compelling success story in this transformation.2 For sponsors, the challenge is no longer identifying promising mechanisms alone, but designing development programmes capable of demonstrating value in increasingly precise patient populations.

Biologics in eosinophilic COPD: A transformative step

Significant advances have occurred in eosinophilic COPD, where biologic therapies targeting T2 inflammation have demonstrated meaningful clinical benefits. Dupilumab, the first biologic approved for COPD in 20243, blocks IL 4 and IL 13 signaling and has shown ~30–34% reductions in exacerbations along with improved lung function in patients with blood eosinophils ≥300 cells/µL. Alongside this, mepolizumab and benralizumab, which target the IL 5 pathway, reduce eosinophil survival or deplete eosinophils directly, leading to moderate reductions in exacerbations particularly in biomarker selected populations with higher eosinophil levels. While dupilumab currently demonstrates the strongest clinical outcomes, these therapies together confirm that eosinophilic inflammation is a viable and actionable therapeutic target in COPD, thereby laying the groundwork for a precision medicine approach to disease management. Beyond their clinical benefit, these programmes provide important lessons for future development. They highlight the importance of biomarker strategy, patient selection and endpoint optimisation in demonstrating treatment effect within heterogeneous COPD populations.

The next frontier: Clinical trial innovation and pipeline expansion

As the first wave of biologics establishes proof of concept, the drug development landscape in COPD is rapidly evolving not only in terms of novel molecules but also in how clinical trials are designed and conducted.

1. Biomarker enriched and adaptive trial designs

Recent COPD trials increasingly incorporate biomarker-based enrichment, to identify patients most likely to benefit from targeted treatments, particularly biologics. In parallel, adaptive trial methodologies allow modifications during the study such as dose adjustments or cohort refinement based on interim results, improving efficiency and success rates. Additionally, trial designs now incorporate stratification strategies that account for variability in eosinophil levels caused by factors such as infections, corticosteroid use, and circadian fluctuations4. Collectively, these advances reflect a larger transition toward precision medicine, similar to advances already seen in oncology and asthma5. One of the key challenges facing development teams is that biomarker-driven studies are often more complex than they appear on paper. Early decisions regarding enrichment criteria, site selection and endpoint strategy can materially influence recruitment efficiency and data interpretability.

 

2. Platform trials and real-world integration

At the same time, the future of COPD drug development is being shaped by platform trials and the integration of real world data (RWD). Platform trials enable the simultaneous evaluation of multiple therapies within a shared infrastructure, improving comparative understanding while increasing development efficiency. The incorporation of RWD further complements traditional randomised controlled trials by capturing outcomes in more diverse patient populations.

Emerging tools such as digital biomarkers, including wearable based symptom monitoring, are also improving the ability to track exacerbations and disease patterns in real time. Together, these approaches have the potential to address long-standing challenges in COPD research, including patient heterogeneity, recruitment barriers, and limited generalisability of trial results. For sponsors, they may also support more efficient evidence generation and provide a more comprehensive understanding of treatment effectiveness in routine clinical practice.

Emerging therapies

Beyond established biologics, the COPD pipeline is rapidly expanding, with more than 70 therapies in development across over 65 companies6, reflecting intense global investment in novel mechanisms. As the development landscape becomes increasingly competitive, differentiation will be defined not only by mechanism of action but by the strength of evidence generated for regulators, clinicians, payers and healthcare systems. A major focus is on upstream inflammatory mediators, or “alarmins,” such as IL‑33 and TSLP. Agents like tezepelumab (anti‑TSLP) and IL‑33 pathway inhibitors (itepekimab and astegolimab) have shown mixed results to date, with modest improvements in lung function but largely inconclusive effects on exacerbation reduction. In contrast, the anti‑IL‑33 antibody tozorakimab has demonstrated promising efficacy signals after showing meaningful after demonstrating meaningful reductions in exacerbations across a broad COPD population, independent of eosinophil levels, suggesting the potential to move beyond strict biomarker-based patient selection.

Alongside biologics, non-biologic developments also remain relevant, particularly ensifentrine, a dual PDE3/PDE4 inhibitor that provides combined bronchodilator and anti-inflammatory effects and represents the first new inhaled bronchodilator class, offering a valuable adjunct or step-up option before initiating biologic therapy.

Conclusion

COPD is undergoing a transformation from a broadly treated condition to a precision medicine-driven disease area. Eosinophilic COPD has led this shift, with several biologics validating targeted approaches to inflammation.

At the same time, innovations in clinical trial design and an expanding pipeline of anti-alarmin therapies and novel non-biologics are reshaping the future of COPD drug development.

The coming years are likely to bring even greater refinement, with therapies tailored not only to symptoms, but also to the underlying biology of individual patients. As our understanding of COPD heterogeneity continues to evolve, so too will opportunities to develop more targeted therapies for well-defined patient populations, bringing the field closer to a truly precision medicine approach to COPD care.

References

  1. Bhatt, S.P., Freemantle, N., Soliman, M. et al. Dupilumab Versus Mepolizumab for COPD: Evaluating Efficacy Outcomes Using Placebo-Adjusted Indirect Treatment Comparison. Pulm Ther 12, 201–217 (2026). https://doi.org/10.1007/s41030-025-00322-1
  2. Qi Q, Peng W, Yang B, Liu S, Pu Y and Zhou Q (2026) Biologics for eosinophilic COPD: current applications and future prospects. Front. Immunol. 17:1722371. doi: 10.3389/fimmu.2026.1722371
  3. Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
  4. Candia C, Merola C, Fuschillo S ...Short term variability of peripheral blood eosinophil count in individuals with stable COPD. European Journal of Internal Medicine, 2025; 139
  5. Pascoe S, Barnes N, Brusselle G et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. The Lancet Respiratory Medicinee, 2019; 7, 745-756
  6. COPD Clinical Trials Pipeline 2025: COPD FDA Approvals, Therapy Innovations, and Emerging Landscape Analysis by DelveInsight | Amgen, Synairgen, AstraZeneca, Sanofi, Organicell Regenerative Medicine | ABNewswire
In this section

Connect with us